Annual CFO
$104.16 M
+$645.43 M+119.24%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual cash flow from operations is currently $104.16 million, with the most recent change of +$645.43 million (+119.24%) on 31 December 2023. During the last 3 years, it has risen by +$719.12 million (+116.94%). ALNY annual CFO is now -47.00% below its all-time high of $196.52 million, reached on 31 December 2007.ALNY Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$43.71 M
-$80.45 M-64.80%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly cash flow from operations is currently $43.71 million, with the most recent change of -$80.45 million (-64.80%) on 30 September 2024. Over the past year, it has dropped by -$315.70 million (-87.84%). ALNY quarterly CFO is now -87.84% below its all-time high of $359.41 million, reached on 30 September 2023.ALNY Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$56.55 M
-$315.70 M-84.81%
30 September 2024
Summary:
Alnylam Pharmaceuticals TTM cash flow from operations is currently $56.55 million, with the most recent change of -$315.70 million (-84.81%) on 30 September 2024. Over the past year, it has increased by +$54.58 million (+2766.45%). ALNY TTM CFO is now -84.81% below its all-time high of $372.26 million, reached on 30 June 2024.ALNY TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +119.2% | -87.8% | +2766.4% |
| 3 y3 years | +116.9% | +132.6% | +109.2% |
| 5 y5 years | +118.5% | +123.9% | +124.3% |
ALNY Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +116.2% | -87.8% | +125.5% | -84.8% | +108.8% |
| 5 y | 5 years | at high | +116.2% | -87.8% | +117.8% | -84.8% | +107.4% |
| alltime | all time | -47.0% | +116.2% | -87.8% | +117.8% | -84.8% | +107.4% |
Alnylam Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $43.71 M(-64.8%) | $56.55 M(-84.8%) |
| June 2024 | - | $124.16 M(-252.3%) | $372.26 M(+96.8%) |
| Mar 2024 | - | -$81.52 M(+173.6%) | $189.12 M(+81.6%) |
| Dec 2023 | $104.16 M(-119.2%) | -$29.80 M(-108.3%) | $104.16 M(+5179.1%) |
| Sept 2023 | - | $359.41 M(-709.3%) | $1.97 M(-100.4%) |
| June 2023 | - | -$58.99 M(-64.6%) | -$472.72 M(-11.9%) |
| Mar 2023 | - | -$166.47 M(+26.1%) | -$536.56 M(-0.9%) |
| Dec 2022 | -$541.27 M(-15.6%) | -$131.98 M(+14.5%) | -$541.27 M(-3.2%) |
| Sept 2022 | - | -$115.28 M(-6.1%) | -$559.44 M(-3.2%) |
| June 2022 | - | -$122.82 M(-28.3%) | -$578.19 M(+0.2%) |
| Mar 2022 | - | -$171.19 M(+14.0%) | -$577.23 M(-10.0%) |
| Dec 2021 | -$641.69 M(+4.3%) | -$150.14 M(+12.0%) | -$641.69 M(+4.4%) |
| Sept 2021 | - | -$134.04 M(+10.0%) | -$614.70 M(+4.0%) |
| June 2021 | - | -$121.86 M(-48.3%) | -$590.99 M(-2.2%) |
| Mar 2021 | - | -$235.66 M(+91.4%) | -$604.46 M(-1.7%) |
| Dec 2020 | -$614.96 M(+120.9%) | -$123.14 M(+11.6%) | -$614.96 M(-10.6%) |
| Sept 2020 | - | -$110.33 M(-18.5%) | -$687.80 M(-9.5%) |
| June 2020 | - | -$135.33 M(-45.0%) | -$760.10 M(+126.2%) |
| Mar 2020 | - | -$246.16 M(+25.6%) | -$336.08 M(+20.7%) |
| Dec 2019 | -$278.43 M(-50.5%) | -$195.98 M(+7.3%) | -$278.43 M(+19.5%) |
| Sept 2019 | - | -$182.63 M(-163.3%) | -$232.90 M(+14.1%) |
| June 2019 | - | $288.69 M(-253.1%) | -$204.08 M(-65.7%) |
| Mar 2019 | - | -$188.51 M(+25.3%) | -$595.46 M(+5.8%) |
| Dec 2018 | -$562.62 M(+47.0%) | -$150.46 M(-2.2%) | -$562.62 M(+9.2%) |
| Sept 2018 | - | -$153.81 M(+49.8%) | -$515.20 M(+12.1%) |
| June 2018 | - | -$102.69 M(-34.0%) | -$459.76 M(+4.9%) |
| Mar 2018 | - | -$155.66 M(+51.1%) | -$438.12 M(+14.5%) |
| Dec 2017 | -$382.79 M(+24.4%) | -$103.04 M(+4.8%) | -$382.79 M(+6.9%) |
| Sept 2017 | - | -$98.36 M(+21.4%) | -$358.08 M(+6.8%) |
| June 2017 | - | -$81.05 M(-19.2%) | -$335.25 M(+3.3%) |
| Mar 2017 | - | -$100.33 M(+28.1%) | -$324.41 M(+5.4%) |
| Dec 2016 | -$307.70 M(+62.7%) | -$78.34 M(+3.7%) | -$307.70 M(+8.9%) |
| Sept 2016 | - | -$75.54 M(+7.6%) | -$282.43 M(+8.1%) |
| June 2016 | - | -$70.20 M(-16.0%) | -$261.26 M(+6.0%) |
| Mar 2016 | - | -$83.62 M(+57.6%) | -$246.51 M(+30.3%) |
| Dec 2015 | -$189.14 M(+14.2%) | -$53.06 M(-2.4%) | -$189.14 M(+9.5%) |
| Sept 2015 | - | -$54.37 M(-2.0%) | -$172.71 M(+8.6%) |
| June 2015 | - | -$55.46 M(+111.2%) | -$159.05 M(+5.9%) |
| Mar 2015 | - | -$26.25 M(-28.3%) | -$150.22 M(-9.3%) |
| Dec 2014 | -$165.64 M | -$36.63 M(-10.0%) | -$165.64 M(+9.4%) |
| Sept 2014 | - | -$40.71 M(-12.7%) | -$151.38 M(+14.3%) |
| June 2014 | - | -$46.63 M(+11.9%) | -$132.38 M(+21.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$41.67 M(+86.3%) | -$109.36 M(+59.3%) |
| Dec 2013 | -$68.66 M(-40.6%) | -$22.37 M(+3.0%) | -$68.66 M(-40.4%) |
| Sept 2013 | - | -$21.71 M(-8.0%) | -$115.20 M(+30.5%) |
| June 2013 | - | -$23.60 M(+2330.7%) | -$88.27 M(+2.2%) |
| Mar 2013 | - | -$971.00 K(-98.6%) | -$86.36 M(-25.3%) |
| Dec 2012 | -$115.61 M(+32.8%) | -$68.91 M(-1422.2%) | -$115.61 M(+60.9%) |
| Sept 2012 | - | $5.21 M(-124.0%) | -$71.86 M(-32.3%) |
| June 2012 | - | -$21.69 M(-28.2%) | -$106.09 M(-4.4%) |
| Mar 2012 | - | -$30.21 M(+20.1%) | -$110.98 M(+27.5%) |
| Dec 2011 | -$87.07 M(+3.2%) | -$25.16 M(-13.3%) | -$87.07 M(+5.8%) |
| Sept 2011 | - | -$29.02 M(+9.2%) | -$82.30 M(+6.5%) |
| June 2011 | - | -$26.58 M(+321.6%) | -$77.31 M(+3.0%) |
| Mar 2011 | - | -$6.30 M(-69.1%) | -$75.05 M(-11.0%) |
| Dec 2010 | -$84.34 M(+16.9%) | -$20.39 M(-15.2%) | -$84.34 M(+4.4%) |
| Sept 2010 | - | -$24.04 M(-1.1%) | -$80.82 M(+4.5%) |
| June 2010 | - | -$24.31 M(+55.8%) | -$77.37 M(-13.0%) |
| Mar 2010 | - | -$15.60 M(-7.5%) | -$88.98 M(+23.3%) |
| Dec 2009 | -$72.14 M(-210.2%) | -$16.87 M(-18.1%) | -$72.14 M(+20.0%) |
| Sept 2009 | - | -$20.59 M(-42.7%) | -$60.13 M(+8.2%) |
| June 2009 | - | -$35.92 M(-3017.9%) | -$55.55 M(-173.7%) |
| Mar 2009 | - | $1.23 M(-125.4%) | $75.38 M(+15.1%) |
| Dec 2008 | $65.49 M(-66.7%) | -$4.85 M(-69.7%) | $65.49 M(+5.8%) |
| Sept 2008 | - | -$16.01 M(-116.9%) | $61.90 M(-79.5%) |
| June 2008 | - | $95.01 M(-1197.3%) | $302.22 M(+52.0%) |
| Mar 2008 | - | -$8.66 M(+2.6%) | $198.82 M(+1.2%) |
| Dec 2007 | $196.52 M(-897.9%) | -$8.44 M(-103.8%) | $196.52 M(-1.9%) |
| Sept 2007 | - | $224.31 M(-2773.2%) | $200.34 M(-844.9%) |
| June 2007 | - | -$8.39 M(-23.4%) | -$26.90 M(+0.0%) |
| Mar 2007 | - | -$10.96 M(+137.6%) | -$26.89 M(+9.2%) |
| Dec 2006 | -$24.63 M(+49.4%) | -$4.61 M(+57.3%) | -$24.63 M(+50.2%) |
| Sept 2006 | - | -$2.93 M(-65.0%) | -$16.40 M(-16.7%) |
| June 2006 | - | -$8.38 M(-3.7%) | -$19.68 M(+12.1%) |
| Mar 2006 | - | -$8.70 M(-340.7%) | -$17.55 M(+6.5%) |
| Dec 2005 | -$16.48 M(-15.8%) | $3.62 M(-158.2%) | -$16.48 M(-21.9%) |
| Sept 2005 | - | -$6.21 M(-0.6%) | -$21.12 M(+14.0%) |
| June 2005 | - | -$6.25 M(-18.2%) | -$18.52 M(-1.1%) |
| Mar 2005 | - | -$7.64 M(+651.9%) | -$18.71 M(-4.4%) |
| Dec 2004 | -$19.57 M(+52.6%) | -$1.02 M(-71.9%) | -$19.57 M(+5.5%) |
| Sept 2004 | - | -$3.61 M(-44.0%) | -$18.55 M(+24.2%) |
| June 2004 | - | -$6.45 M(-24.1%) | -$14.94 M(+75.9%) |
| Mar 2004 | - | -$8.49 M | -$8.49 M |
| Dec 2003 | -$12.83 M(+903.8%) | - | - |
| Dec 2002 | -$1.28 M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual CFO year-on-year change?
- What is Alnylam Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly CFO year-on-year change?
- What is Alnylam Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM CFO year-on-year change?
What is Alnylam Pharmaceuticals annual cash flow from operations?
The current annual CFO of ALNY is $104.16 M
What is the all time high annual CFO for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual cash flow from operations is $196.52 M
What is Alnylam Pharmaceuticals annual CFO year-on-year change?
Over the past year, ALNY annual cash flow from operations has changed by +$645.43 M (+119.24%)
What is Alnylam Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of ALNY is $43.71 M
What is the all time high quarterly CFO for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly cash flow from operations is $359.41 M
What is Alnylam Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, ALNY quarterly cash flow from operations has changed by -$315.70 M (-87.84%)
What is Alnylam Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of ALNY is $56.55 M
What is the all time high TTM CFO for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM cash flow from operations is $372.26 M
What is Alnylam Pharmaceuticals TTM CFO year-on-year change?
Over the past year, ALNY TTM cash flow from operations has changed by +$54.58 M (+2766.45%)